- Home
- ORGN vs ADAG Comparison
ORGN vs ADAG Comparison
Compare ORGN & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGN
- ADAG
- Stock Information
- Founded
- ORGN 2008
- ADAG 2011
- Country
- ORGN United States
- ADAG China
- Employees
- ORGN N/A
- ADAG N/A
- Industry
- ORGN Major Chemicals
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- ORGN Industrials
- ADAG Health Care
- Exchange
- ORGN Nasdaq
- ADAG Nasdaq
- Market Cap
- ORGN 124.1M
- ADAG 100.5M
- IPO Year
- ORGN N/A
- ADAG 2021
- Fundamental
- Price
- ORGN $1.43
- ADAG $2.16
- Analyst Decision
- ORGN Strong Buy
- ADAG Strong Buy
- Analyst Count
- ORGN 1
- ADAG 1
- Target Price
- ORGN $3.00
- ADAG $5.00
- AVG Volume (30 Days)
- ORGN 1.3M
- ADAG 89.5K
- Earning Date
- ORGN 11-07-2024
- ADAG 07-25-2024
- Dividend Yield
- ORGN N/A
- ADAG N/A
- EPS Growth
- ORGN N/A
- ADAG N/A
- EPS
- ORGN N/A
- ADAG N/A
- Revenue
- ORGN $34,061,000.00
- ADAG $815,746.00
- Revenue This Year
- ORGN $10.62
- ADAG N/A
- Revenue Next Year
- ORGN $175.99
- ADAG $2.70
- P/E Ratio
- ORGN N/A
- ADAG N/A
- Revenue Growth
- ORGN 295.97
- ADAG N/A
- 52 Week Low
- ORGN $0.44
- ADAG $1.30
- 52 Week High
- ORGN $1.90
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- ORGN 45.24
- ADAG 41.64
- Support Level
- ORGN $1.40
- ADAG $2.12
- Resistance Level
- ORGN $1.51
- ADAG $2.41
- Average True Range (ATR)
- ORGN 0.08
- ADAG 0.16
- MACD
- ORGN -0.03
- ADAG -0.00
- Stochastic Oscillator
- ORGN 4.72
- ADAG 10.43
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.